La vendita allo scoperto per Merck & Co dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Merck & Co. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Merck & Co (NYSE:MRK) Azioni, Report sulle vendite allo scoperto

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Long Ideas

News

Markets

Media

Trading Ideas

ENVA

FTNT

GEHC

PANW

TDOC

Jim Cramer si dice deluso per aver scelto GE HealthCare come la peggiore delle tre azioni. Ecco che cosa è successo.

Jim Cramer desolato: ha comprato la &#34;peggiore delle tre&#34;

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Biotech

Downgrades

Health Care

Analyst Ratings

Movers

General

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

"The innovative research that will be presented at this year's ASH highlights our robust clinical development program and our commitment to exploring novel modalities and therapeutic targets, as we work to improve outcomes and address unmet needs for people with hematologic neoplasms and malignancies," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.&nbsp;

Merck To Present New Data For Approved And Investigational Medicines Across Multiple Hematologic Malignancies At ASH Annual Meeting From Dec. 7-10

<a href="https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.">https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.</a>
Johnson &amp; Johnson and Merck &amp; Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing's campaign to drive down medical costs.
Both US drug giants have laid off employees in China in recent days, according to people familiar with the matter who asked not to be identified discussing internal matters. The J&amp;J cuts mainly impacted a division that sells products used in surgery, while Merck scaled back in its diabetes unit, the people said.&nbsp;
Chinese media outlets, which were first to report the redundancies, cited the J&amp;J layoffs to be as much as a fifth of its mainland workforce. J&amp;J employs nearly 10,000 people across some 90 cities in China, according to its website.&nbsp;
J&amp;J "has recently implemented organizational changes to optimise our business operations" in the country, a company spokesperson told Bloomberg in an email. J&amp;J remains committed to the "critical and growing" China market, the spokesperson added.&nbsp;
Merck didn't immediately reply to a request for comment outside regular business hours.&nbsp;
Multinational drug and medical device makers are grappling with narrower profit margins in China, largely due to the country's system of having companies bid to supply drugs and devices to public hospitals — known as volume-based procurement (VBP). The program has seen global pharmaceutical companies lose hospital contracts for their top off-patent drugs and devices to cheaper local suppliers, essentially putting their sales team out of work in those categories.
The layoffs add to turmoil in the pharmaceutical market in China. Once seen as a big market opportunity for global drugmakers to expand, they've come under regulatory pressure on multiple fronts. AstraZeneca, which has seen China revenue growth slow due in part to losing hospital contracts for its off-patent medicines, is facing a criminal investigation into allegedly illegal sales practices which has ensnared its China chief.&nbsp;
In a recent earnings call, J&amp;J executives acknowledged a "disproportionate impact from VBP" thanks to its being the largest medtech company in China. The layoffs are the first major round of redundancies affecting the company's surgery division, a person familiar with the matter said, though layoffs in other departments have been ongoing for some time.&nbsp;
Meanwhile, Merck is set to face off against local suppliers for generic versions of two major diabetes drugs – Januvia and Janumet – in the latest round of VBP tender submissions.&nbsp;

Management

Reported Earlier, "J&J, Merck Cut Jobs in China As Local Competition Takes Toll" - BNN Bloomberg

<a href="https://x.com/MarkKleinmanSky/status/1858942117827018868" title="https://x.com/MarkKleinmanSky/status/1858942117827018868">https://x.com/MarkKleinmanSky/status/1858942117827018868</a>

INCY

Watching Incyte; Sky News City Editor Mark Kleinman Posts On X "Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte, With Which It Collaborates On Several Drug Development Projects."

On Tuesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration of pembrolizumab together with berahyaluronidase alfa, administered with chemotherapy versus intravenous (IV) Keytruda administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42058324/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primar" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Pembrolizumab is available for intravenous use as Keytruda,
Berahyaluronidase alfa is a hyaluronidase variant developed and manufactured by Alteogen Inc.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s WHy</a>
The Phase 3 trial met its dual primary pharmacokinetic (PK) endpoints.
Specifically, subcutaneous pembrolizumab administered every six weeks with chemotherapy demonstrated noninferiority of Area Under the Curve (AUC) exposure of pembrolizumab during the first dosing cycle, and trough concentration (Ctrough) of pembrolizumab measured at steady state, compared to IV Keytruda administered every six weeks in combination with chemotherapy.
Additionally, secondary efficacy and safety endpoints were generally consistent for subcutaneous pembrolizumab administered with chemotherapy compared with IV Keytruda administered with chemotherapy.
These results and those from ongoing analyses will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
In addition to the Phase 3 MK-3475A-D77 trial, Merck&#8217;s subcutaneous pembrolizumab clinical development program includes the Phase 3 MK-3475A-F84 trial evaluating subcutaneous pembrolizumab administered alone compared to IV Keytruda for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression, as well as the Phase 2 MK-3475A-F65 trial evaluating subcutaneous pembrolizumab administered alone in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Merck is also conducting a Phase 2 patient preference study, MK-3475A-F11, evaluating participant-reported preference for subcutaneous pembrolizumab compared to IV Keytruda.
Price Action: MRK stock is down 0.56% at $96.03 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42062234/whats-going-on-with-nio-stock-following-strong-q3-results-from-top-peer-xpeng" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With NIO Stock Following Strong Q3 Results From Top Peer XPeng?</a></li>
</ul>
Photo Courtesy of Merck

Large Cap

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024.

Dividends

Merck Increases Quarterly Dividend From $0.77 To $0.81 Per Share

Merck shares are trading higher after the company reported topline results from its pivotal Phase 3 MK-3475A-D77 trial, which met its dual primary pharmacokinetic endpoints.

Additionally, secondary endpoints of efficacy and safety were generally consistent for subcutaneous pembrolizumab administered with chemotherapy compared with IV KEYTRUDA administered with chemotherapy. These results, as well as those from ongoing analyses, will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.

Merck Reports Topline Results From Pivotal Phase 3 MK-3475A-D77 Trial; Says Trial Met Its Dual Primary Pharmacokinetic Endpoints

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-15_08h38_46.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Powell Speaks The Truth</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-powell-speech-trump-appointments-spy-mc-11152024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>It is worth a reminder that The Arora Report is politically agnostic.&nbsp; Our sole job is to help our members extract the maximum amount of money out of the markets with the least possible risk.</li>
<li>The price action on the chart shows that the rip roaring Trump rally is taking a breather.</li>
<li>The chart shows that the stock market is still above the breakout line.</li>
<li>RSI on the chart shows that the stock market has pulled back, reflecting a loss of momentum. The stock market is still overbought.</li>
<li>The chart shows that the volume remains low.&nbsp; This indicates that institutional investors are not rushing to buy stocks.</li>
<li>Yesterday, Powell spoke that truth – the market did not like it.&nbsp; Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates."&nbsp; Powell elaborated, "The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully."</li>
<li>Powell's remarks brought some selling into stocks and bonds.</li>
<li>This morning, in the early trade, selling continues.</li>
<li>The reason for some selling is that the prevailing wisdom on Wall Street has been that another rate cut in December was a sure thing.&nbsp; The Arora Report has been questioning Wall Street's wisdom and sharing with you that the data does not support another rate cut.</li>
<li>Some conservative commentators are upset believing that the reason Powell started rate cuts with a 50 bps cut was to help Kamala Harris get elected.&nbsp; Now that Trump has been elected, Powell is in no hurry to cut rates.</li>
<li>In The Arora Report analysis, even though the data does not support a rate cut in December, Powell is going to feel pressure from Trump and Republicans to cut rates.&nbsp; There is also a significant amount of data between now and the December Fed meeting.</li>
<li>In The Arora Report analysis, based on a 360 degree view, including the political pressure and the pressure from Wall Street to cut rates, the probability of a rate cut in December is now about 60%.&nbsp;&nbsp;</li>
<li>There is consternation about several Trump picks.&nbsp; Impacting the market most are Trump's picks of RKF Jr, Matt Gaetz, and Pete Hegseth.&nbsp; These picks are bringing selling in vaccine makers such as Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).&nbsp; There is also selling in other healthcare stocks, including weight loss drug companies Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and packaged food stocks such as The Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>).&nbsp; There is also selling in defense stocks such as Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).&nbsp; There is also selling in big tech stocks.</li>
<li>The latest economic data is strong.&nbsp; The U.S. economy is about 70% consumer based.&nbsp; For this reason, prudent investors pay attention to retail sales.&nbsp; Here are the details of the just released data:
<ul>
<li>Retail sales came at 0.4% vs. 0.3% consensus.</li>
<li>Retail sales ex-auto came at 0.1% vs. 0.2% consensus.</li>
</ul>
</li>
<li>There are hundreds of indicators.&nbsp; At The Arora Report, the system has been refined through decades of research to share with you only those indicators that matter.&nbsp; Normally, we do not mention the NY Fed Empire State Manufacturing Index.&nbsp; Today, we are mentioning it due to its exceptional strength.&nbsp; The index came at 31.2 vs. 3.3 consensus.&nbsp; This indicates that manufacturing in the New York area has picked up steam. &nbsp; If similar strength is happening in the rest of the country, that would argue against further cutting interest rates. The problem for investors is that stock valuations are so high that to sustain them, rate cuts are needed.&nbsp;&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Even the slightest dips in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are being bought.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Federal Reserve

$BTC

AAPL

AMZN

BNTX

GOOG

MRNA

MSFT

NVAX

NVDA

TSLA

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Eurozone

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

"The CHMP's positive opinion marks an important milestone for patients in Europe with non-epithelioid mesothelioma, who experience worse survival outcomes than patients with epithelioid mesothelioma," said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. "The positive CHMP opinion moves us closer to offering a new first-line treatment option with a proven overall survival benefit for certain patients in the European Union with this difficult-to-treat cancer."

Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult  Patients With Unresectable Non-epithelioid Malignant Pleural Mesothelioma

Wolfe Research analyst Alexandria Hammond initiates coverage on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Merck & Co with Peer Perform Rating

On Thursday, Immutep Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41970785/immuteps-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer" rel="noreferrer noopener">cancer (1L NSCLC) patients</a>.
The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:
<ul>
<li>Median Overall Survival (OS) of 32.9 months.</li>
<li>Median Progression-Free Survival (PFS) of 12.7 months.</li>
<li>24-month Overall Survival (OS) of 81.0%.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39747049/australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-h" rel="noreferrer noopener">Australia Based Cancer Focused Immutep&#8217;s Lead Cancer Drug Shows &#8216;Meaningful Response&#8217; In Untreated Head &amp; Neck Cancer, Stock Soars</a>
The company compares the data with the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC regardless of PD-L1 expression.
Marc Voigt, CEO of Immutep, said, &#8220;The overall survival and progression-free survival data from this mature cohort of patients in INSIGHT-003 with nearly a 2-year minimum followup exceeds our expectations.&#8221;
Data from all evaluable patients to date (N=40) demonstrates significant improvement in Overall Response Rate (ORR) across all levels of PD-L1 expression compared to historical control:
<ul>
<li>75.0% ORR versus 62.1% ORR in patients with high PD-L1 expression.</li>
<li>58.8% ORR versus 49.2% ORR in patients with low PD-L1 expression.</li>
<li>47.4% ORR versus 32.3% ORR in patients with negative PD-L1.</li>
<li>In this all-comer PD-L1 trial, the 55.0% ORR and 87.5% Disease Control Rate (DCR) are from the following breakdown of patients by PD-L1 expression: high PD-L1 expression (N=4), low PD-L1 expression (N=17), and negative PD-L1 (N=19).</li>
<li>Compared to the general 1L NSCLC patient population, each of these PD-L1 levels represents roughly one-third, INSIGHT-003 is biased towards low and negative PD-L1 patients who are typically less responsive to anti-PD-1 therapy.</li>
<li>In these patients with low and negative PD-L1 expression (36 of 40 patients), the triple combination achieved a 52.8% ORR and 86.1% DCR.</li>
</ul>
INSIGHT-003, a multi-centre study led by the Frankfurt Institute of Clinical Cancer Research IKF, is nearing completion of patient enrolment.
Additional data updates from this trial are expected in 2025 and beyond.
Price Action: IMMP stock is up 9.6% at $2.05 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41970133/exclusive-adial-pharmaceuticals-reveals-topline-results-from-pharmacokinetics-study-of-ad04-for-alcohol-use-disorder" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder</a></li>
</ul>
Photo: Shutterstock

IMMP

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of $588 million.&nbsp;
LaNova is also eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer, development, regulatory approval and commercialization of LM-299 across multiple indications.

Contracts

Merck Enters Exclusive Global License With LaNova For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody; LaNova To Receive Upfront Payment Of $588 And Receive Up To $2.7B In Milestone Payments

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PTGX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Results demonstrated reduction in tumour volume, building on established safety and efficacy profile of Koselugo in children and supporting expanded use in adults&nbsp;
Results demonstrated reduction in tumour volume, building on established safety and efficacy profile of Koselugo in children and supporting expanded use in adults &nbsp;

AstraZeneca's High-Level Results From KOMET Phase 3 Trial In Adults With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Showed That Koselugo (Selumetinib) Met Its Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Objective Response Rate Versus Placebo

Merck To Showcase GARDASIL®9 Data At IPVC 2024, Emphasizing HPV Vaccination For Adults Up To Age 45

Merck (NYSE:&nbsp;MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR&#xAE; (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.

Global

Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. 
According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. 
This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.
Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. 
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. 
Similarly, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.
Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. 
Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.
On the downside, Wegovy maker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.
Similarly, Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. 
Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.
&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why">ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</a></li>
</ul>
Image Via Shutterstock

ABBV

ALNY

GILD

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Truist Securities analyst Robyn Karnauskas maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $132 to $130.

Price Target

Truist Securities Maintains Buy on Merck & Co, Lowers Price Target to $130

Johnson & Johnson (JNJ) and Merck (MRK) are cutting jobs in China as they face growing competition from domestic rivals resulting from Beijing's ca...

Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Target (TGT) reported downbeat Q3 resu...

Target reports downbeat Q3, Comcast plans cable TV spinoff: Morning Buzz

Absci Corporation: Struggling To Live Up To Its AI Promise

Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of so...

Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck

Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset

Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade

Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference

Franklin Corefolio Allocation Fund Q3 2024 Commentary

Citi Research's U.S. Equity Strategy Large-Cap recommendation list

Optimism over global healthcare sector rises: Jefferies

ABSI

ASML

BIIB

CHWY

CMCSA

EXAI

GLBE

GMAB

GOOGL

HBAN

ISRG

LPLA

LRHC

MRUS

MRVL

NOVA

ORCL

PDYN

PLTR

QUBT

RCAT

RLAY

ROKU

SNOW

SNYNF

WING

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement

Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024

KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck to Participate in the Jefferies London Healthcare Conference

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

Merck Announces First-Quarter 2025 Dividend

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

AGEN

LGND

TVTX

VRNA

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Comments

Merck & Co

Vendite allo scoperto

Merck & Co (NYSE:MRK) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO